Drug intelligence / Profile preview

Xla1

Development stage: Phase 1
Lead developer: YSOPIA Bioscience
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Xla1 is a live biotherapeutic product (LBP) containing a single bacterial strain of *Christensenella minuta* DSM 33407 as its active substance. It is being developed for the treatment of obesity and associated metabolic disorders. The drug is administered as an oral capsule. Xla1 works by modulating the gut microbiome, as Christensenella is a keystone bacteria of healthy human gut microbiome whose absence is linked to obesity and metabolic disorders. The relative abundance of Christensenella in the human gut is inversely related to host body mass index (BMI) and to the presence of several metabolic disease markers. Preclinical studies have demonstrated substantial efficacy of Xla1 on obesity and related metabolic markers.

Other names: Christensenella minuta DSM 33407

Beyond the preview

Go deeper on Xla1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xla1.

Explore the full profile